aibioELTP Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals (ELTP) news
Top story · Aug 13, 2026 · Company press release
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 ended June 30, 2026 and Provides Conference Call Information
at 11:30 AM EDT Northvale, NJ – August 13, 2026: Elite Pharmaceuticals, Inc.
Latest Elite Pharmaceuticals news
We have not published a story on Elite Pharmaceuticals yet. When there is news, it will appear here.
What Elite Pharmaceuticals does
Elite Pharmaceuticals develops, manufactures and sells pharmaceutical products, including branded drug products approved under New Drug Applications and generic drug products approved under Abbreviated New Drug Applications. The company says it owns, licenses, manufactures, sells, distributes or receives royalties from a diverse product portfolio. Its commercial products include phentermine hydrochloride tablets and capsules, a bariatric product sold under the Adipex-P brand equivalent, and phendimetrazine tartrate tablets, sold under the Bontril brand equivalent. It also sells naltrexone hydrochloride tablets for pain, isradipine capsules for cardiovascular use, trimipramine maleate capsules as an antidepressant, and immediate release amphetamine tablets as a central nervous system stimulant. Each of these products is listed in the filing with its launch date, which runs from April 2011 onward. The company states that its business strategy reduces its risk by having a diverse product portfolio.
| Product or program | What it is | Stage |
|---|---|---|
| Phentermine HCl tablets and capsules | Bariatric product, Adipex-P equivalent | Commercially sold |
| Phendimetrazine tartrate tablets | Bariatric product, Bontril equivalent | Commercially sold |
| Naltrexone HCl tablets | Pain product, Revia equivalent | Commercially sold |
| Isradipine capsules | Cardiovascular product | Commercially sold |
| Trimipramine maleate capsules | Antidepressant, Surmontil equivalent | Commercially sold |
| Amphetamine IR tablets | Central nervous system stimulant, Adderall equivalent | Commercially sold |
Elite Pharmaceuticals annual financials
| Line | FY ended Mar 31, 2026 | FY ended Mar 31, 2025 |
|---|---|---|
| Research and development | $5.7 million | $8.0 million |
| Net income (loss) | $44.9 million | -$4.3 million |
| Cash from operations | $23.7 million | $7.5 million |
| Cash and equivalents | $30.3 million | $11.8 million |
Questions about Elite Pharmaceuticals
What is the ticker symbol of Elite Pharmaceuticals?
Elite Pharmaceuticals, Inc. trades under the ticker ELTP on OTC.
Where is Elite Pharmaceuticals listed?
Elite Pharmaceuticals, Inc. is listed on OTC.
What is the SEC CIK of Elite Pharmaceuticals?
The SEC Central Index Key (CIK) for Elite Pharmaceuticals, Inc. is 1053369. Its filings are on SEC EDGAR.
How many shares does Elite Pharmaceuticals have outstanding?
1,077,136,442 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13.
Which country or territory is Elite Pharmaceuticals listed under?
Our directory records Elite Pharmaceuticals, Inc. under United States.
What does Elite Pharmaceuticals do?
Our directory classifies Elite Pharmaceuticals, Inc. as: Pharmaceuticals: Generic. This is a directory classification, not a description of the pipeline.
What is the ISIN of Elite Pharmaceuticals?
The ISIN recorded for Elite Pharmaceuticals, Inc. is US28659T2006.
Does aibio.space cover Elite Pharmaceuticals?
aibio.space lists Elite Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Elite Pharmaceuticals incorporated?
SEC records list its state or country of incorporation as NJ.
What does Elite Pharmaceuticals develop?
Elite Pharmaceuticals develops, manufactures and sells pharmaceutical products, including branded drug products approved under New Drug Applications and generic drug products approved under Abbreviated New Drug Applications. The company says it owns, licenses, manufactures, sells, distributes or receives royalties from a diverse product portfolio.
What is Phentermine HCl tablets and capsules from Elite Pharmaceuticals?
Phentermine HCl tablets and capsules: Bariatric product, Adipex-P equivalent Stage: Commercially sold.
What is Phendimetrazine tartrate tablets from Elite Pharmaceuticals?
Phendimetrazine tartrate tablets: Bariatric product, Bontril equivalent Stage: Commercially sold.
Is Elite Pharmaceuticals profitable?
Elite Pharmaceuticals, Inc. reported net income of $44.9 million for the fiscal year ended Mar 31, 2026, and generated $23.7 million of cash from operations, per its annual report to the SEC.
How much does Elite Pharmaceuticals spend on research and development?
$5.7 million in the fiscal year ended Mar 31, 2026, per its annual report.
How much cash does Elite Pharmaceuticals have?
$39.4 million in cash at Jun 30, 2026, per its 10-Q.
Investor discussion: Elite Pharmaceuticals
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Stock chart
SEC filings and registration
- SEC name
- Elite Pharmaceuticals Inc /Nv/
- CIK
- 1053369
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- ELTP (OTC)
- State or country of incorporation
- NJ
- Fiscal year ends
- March 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 165 LUDLOW AVENUE, NORTHVALE, NJ, 07647
- Phone
- 2017502646
- Shares outstanding
- 1,077,136,442 as of 2026-08-13 (10-Q filed 2026-08-13)
- Former names
- ELITE PHARMACEUTICALS INC /DE/
Recent filings
Listing details
- Company
- Elite Pharmaceuticals, Inc.
- Ticker
- ELTP
- Listing
- OTC
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Generic
- ISIN
- US28659T2006
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction